Hypoxia and Kynurenine Pathway in Periodontal Inflammation

NCT07182448 | Completed

• 1 other identifier: 1124
• Study Type: observational
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

The kynurenine pathway (KP), the primary route for tryptophan (TRP) metabolism, is activated during inflammation and hypoxic conditions, contributing to immune dysregulation and oxidative stress. the interconnected roles of hypoxia, KP activation, and oxidative stress in periodontitis have not been comprehensively investigated.The aim of this study was to determine the role of the kynurenine (KYN) pathway and hypoxia in periodontal inflammation, as well as their association with periodontal clinical parameters.

Conditions

Periodontitis; Diagnose Disease

Keywords

hypoxia; kynurenine; oxidative stress; periodontitis; tryptophan

Outcome Measures

Primary Outcomes (3)

• Pocket probing depth

  Measurement of the depth of a sulcus or periodontal pocket determined by measuring distance from a gingival margin to the base of the sulcus or pocket with a calibrated periodontal probe

  3 months

• Clinical attachment level

  Clinical attachment level (or loss, CAL) is a more accurate indicator of the periodontal support around a tooth than probing depth alone. CAL is measured from a fixed point on the tooth that does not change, the CEJ. To calculate CAL, two measurements are needed: distance from the gingival margin to the CEJ and probing depth. In recession: probing depth (+) gingival margin to the CEJ (add). In tissue overgrowth: probing depth (-) gingival margin to the CEJ (subtract)

  4 months

• Bleeding on probing

  Bleeding on probing referring to bleeding that is induced by gentle manipulation of the tissue at the depth of the gingival sulcus, or interface between the gingiva and a tooth

  4 months

Secondary Outcomes (1)

• serum and saliva analyses for selected molecules

  3 months

Study Arms (2)

Saliva and serum collection of patients and samples molecules analysis

Saliva and serum collection of patients and samples molecules analysis Saliva and serum sampling Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Saliva and serum were then stored at -80 °C until analysis.

Other: Saliva and serum sampling

Salivary and serum TNF-α, HIF-1α, 8-OhdG , KYN, TRP observation

Salivary and serum tumor necrosis factor-alpha (TNF-α), hypoxia-inducible factor-1 alpha (HIF-1α) and 8-hydroxy-2'-deoxyguanosine (8-OhdG) levels were evaluated by ELISA, and salivary and serum KP metabolites were evaluated by liquid chromatography-mass spectrometry.

Other: Saliva and serum sampling

Interventions

Saliva and serum sampling OTHER

Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis.

Saliva and serum collection of patients and samples molecules analysis; Salivary and serum TNF-α, HIF-1α, 8-OhdG , KYN, TRP observation

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Periodontally healthy and stage 3 garde B periodontitis patients were enrolled in this study

You may qualify if:

• systemically healthy
• clinical diagnosis of periodontitis
• clinical diagnosis of periodontal health

You may not qualify if:

• decline to participate and being under 18 \& over 65 years of age;
• having any systemic inflammatory diseases such as diabetes, rheumatoid arthritis, or systemic conditions, including immunodeficiency syndrome, cardiovascular disorders, or hepatic disorders;
• the use of antibiotics and/or anti-inflammatory nonsteroidal anti-inflammatory drugs within 3 months preceding the study;
• having nonsurgical periodontal treatment (previous 6 months);
• having surgical periodontal treatment (previous 12 months);
• having \<20 natural teeth excluding the third molars.

Sponsors & Collaborators

• Istanbul Medipol University Hospital: lead
• Ankara University: collaborator

Study Sites (1)

Istanbul Medipol University

Istanbul, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Periodontitis; Hypoxia

Condition Hierarchy (Ancestors)

Periodontal Diseases; Mouth Diseases; Stomatognathic Diseases; Signs and Symptoms, Respiratory; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Prof

Study Record Dates

• First Submitted: September 11, 2025
• First Posted: September 19, 2025
• Study Start: February 1, 2023
• Primary Completion: April 3, 2024
• Study Completion: August 22, 2024
• Last Updated: September 19, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)